A phase 1/2 trial of HSK39775 Monotherapy in advanced solid tumours, run by Xizang Haisco Pharmaceutical Co., Ltd, now recruiting.
A Study for HSK39775 in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06314373 by Xizang Haisco Pharmaceutical Co., Ltd, with 243 participants planned, started 2024-03-07 and due to reach its primary completion in 2028-02-01. Interventions recorded: HSK39775 Monotherapy.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.